Physical
Pharmacological
Endovascular

Induced Hypertension

  • Improves CBF (possibly more in areas of vasospasm) with associated clinical improvement
  • Noradrenaline safe and usually first line - no risk of increased vasospasm
  • No evidence of new rupture risk
  • No clear BP target or duration:
    • Evidence limited
    • Used on clinical grounds assessing response to therapy or reductions
  • Limited value when infarct established

Euvolaemia

  • Optimises cerebral blood flow
  • Cardiac output monitoring may be useful to guide fluid therapy
  • Hypervolaemia associated with increased complications

Nimodipine

  • Standard dose is 60mg 4 hourly
  • May cause hypotension - if so reduce dose to 30mg 2 hourly
  • Given for 21 days
  • Not used for traumatic SAH

Magnesium

  • No proven benefit
  • Maintenance within normal levels usually advocated

Angiography & stents / intraarterial vasodilators

  • Lower risk of DCI
  • Higher risk of vessel rupture
  • No change in all cause mortality - role unclear
  • Consider in those refractory to medical therapy